Early-stage HER2 – positive( HER2 -+) breast cancer survival outcomes and pathological complete response( pCR ) are forecasted by the HP2DX genomic test. In this study, we assessed the relationship between HER2DX scores and ( i ) pCR in relation to hormone receptor status and various treatment regimens, as well as ii, survival outcome in comparison to cCR status.